Crossmark

Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C

Crossref DOI link: https://doi.org/10.1186/1471-230X-14-131

Published Online: 2014-07-27

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Flores-Contreras, Lucia

Sandoval-Rodríguez, Ana S

Mena-Enriquez, Mayra G

Lucano-Landeros, Silvia

Arellano-Olivera, Inmaculada

Álvarez-Álvarez, Arnulfo

Sanchez-Parada, M Guadalupe

Armendáriz-Borunda, Juan
License Information

License valid from 2014-07-27
More Information

Article History

Received: 17 August 2013

Accepted: 14 July 2014

First Online: 27 July 2014